Paula Anne Newman-Casey1, Taylor Blachley2, Paul P Lee3, Michele Heisler4, Karen B Farris5, Joshua D Stein3. 1. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; University of Michigan Institute for Health Care Policy and Innovation, Ann Arbor, Michigan. Electronic address: panewman@med.umich.edu. 2. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan. 3. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan; University of Michigan Institute for Health Care Policy and Innovation, Ann Arbor, Michigan. 4. University of Michigan Institute for Health Care Policy and Innovation, Ann Arbor, Michigan; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan. 5. School of Pharmacy, University of Michigan, Ann Arbor, Michigan.
Abstract
PURPOSE: To assess longer-term patterns of glaucoma medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. DESIGN: Retrospective, longitudinal cohort analysis. PARTICIPANTS: Beneficiaries aged ≥40 years who were enrolled in a United States (US)-managed care plan for ≥7 years between 2001 and 2012 and newly diagnosed and treated for open-angle glaucoma. METHODS: For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. MAIN OUTCOME MEASURES: Patterns of glaucoma medication adherence. RESULTS: Of the 1234 eligible beneficiaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of persons in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of persons in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of persons in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of persons in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. Persons with the best adherence over 4 years were more likely to be white, to be older, to earn >$60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (β = -0.06/dollar, P = 0.03). CONCLUSIONS: For most patients who were newly prescribed glaucoma medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping patients with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence.
PURPOSE: To assess longer-term patterns of glaucoma medication adherence and identify whether patterns established during the first year of medication use persist during 3 subsequent years of follow-up. DESIGN: Retrospective, longitudinal cohort analysis. PARTICIPANTS: Beneficiaries aged ≥40 years who were enrolled in a United States (US)-managed care plan for ≥7 years between 2001 and 2012 and newly diagnosed and treated for open-angle glaucoma. METHODS: For each enrollee, we quantified medication adherence using the medication possession ratio. Group-based trajectory modeling (GBTM) was applied to identify patterns of adherence for 1 and 4 years of follow-up. The percent of beneficiaries who remained in the same trajectory group in the 1- and 4-year models was tabulated to evaluate group stability. Factors impacting adherence at 1 and 4 years were identified using regression analyses. MAIN OUTCOME MEASURES: Patterns of glaucoma medication adherence. RESULTS: Of the 1234 eligible beneficiaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-year follow-up periods. These groups were as follows: (1) never adherent after their index prescription fill (7.5% and 15.6% of persons in the 1- and 4-year models, respectively); (2) persistently very poor adherence (14.9% and 23.4% of persons in the 1- and 4-year models, respectively); (3) declining adherence (9.5% and 9.1% of persons in the 1- and 4-year models, respectively); (4) persistently moderate adherence (48.1% and 37.0% of persons in the 1- and 4-year models, respectively); and (5) persistently good adherence (20.0% and 15.0% of persons in the 1- and 4-year models, respectively). More than 90% of beneficiaries in the 4 groups with the worst and best adherence patterns (groups 1, 2, 3, 5) maintained their patterns from their first year throughout their 4 years of follow-up. Those with persistently moderate adherence (group 4), the largest group, were most likely to change groups from 1 to 4 years of follow-up. Persons with the best adherence over 4 years were more likely to be white, to be older, to earn >$60 000/year, and to have more eye care visits (P < 0.05 for all comparisons). Those with a higher initial copayment cost had lower adherence rates (β = -0.06/dollar, P = 0.03). CONCLUSIONS: For most patients who were newly prescribed glaucoma medications, adherence patterns observed in the first year of treatment reflect adherence patterns over the subsequent 3 years. Investing resources in both identifying and helping patients with suboptimal adherence patterns over the first year may have a large impact on longer-term adherence.
Authors: Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch Journal: Ophthalmology Date: 2012-06-21 Impact factor: 12.079
Authors: Betsy Sleath; Susan Blalock; David Covert; Jennifer L Stone; Asheley Cockrell Skinner; Kelly Muir; Alan L Robin Journal: Ophthalmology Date: 2011-12 Impact factor: 12.079
Authors: Gemma C M Rossi; Gian Maria Pasinetti; Luigia Scudeller; Rosella Radaelli; Paolo Emilio Bianchi Journal: Eur J Ophthalmol Date: 2011 Jul-Aug Impact factor: 2.597
Authors: Levi N Kanu; Inae Jang; Daniel J Oh; Manpreet S Tiwana; Amy A Mehta; Mark S Dikopf; Thasarat S Vajaranant; Ahmad A Aref; Deepak P Edward Journal: JAMA Ophthalmol Date: 2020-04-01 Impact factor: 7.389
Authors: Jennifer L Hargrove; Virginia Pate; Carri H Casteel; Yvonne M Golightly; Laura R Loehr; Stephen W Marshall; Til Stürmer Journal: Am J Hypertens Date: 2017-10-01 Impact factor: 2.689
Authors: Paula Anne Newman-Casey; Leslie M Niziol; Brenda W Gillespie; Nancy K Janz; Paul R Lichter; David C Musch Journal: Ophthalmology Date: 2020-01-10 Impact factor: 12.079
Authors: Maziar Mohammadi; Kisha Patel; Seyedeh P Alaie; Ron B Shmueli; Cagri G Besirli; Ronald G Larson; Jordan J Green Journal: Acta Biomater Date: 2018-04-21 Impact factor: 8.947
Authors: Paula Anne Newman-Casey; Leslie M Niziol; Paul P Lee; David C Musch; Kenneth Resnicow; Michele Heisler Journal: Ophthalmol Glaucoma Date: 2020-04-30
Authors: Juno Cho; Leslie M Niziol; Paul P Lee; Michele Heisler; Ken Resnicow; David C Musch; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2021-08-04